WHO’s new filovirus guidance unifies Ebola and Marburg care, emphasizing rapid triage, supportive treatment, infection prevention, staff protection, diagnostics, and coordinated outbreak response.

A phase 3 trial found sacituzumab tirumotecan plus pembrolizumab improved progression-free outcomes in first-line PD-L1-positive advanced NSCLC, while survival and safety data remain immature.

FDA cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older without insulin use, expanding access while leaving clinical outcomes uncertain.

FDA cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older without insulin use, expanding access while leaving clinical outcomes uncertain.

FDA recalled one lot of morphine injection after a label mix-up could expose patients to hydromorphone, requiring rapid stop-use, quarantine, verification, and exposure review.

A randomized phase 3 trial supports intravenous fosphenytoin for rapid relief of severe trigeminal neuralgia, emphasizing monitored rescue use rather than maintenance or definitive therapy.

FDA approved RefluxStop for GERD while requiring five-year follow-up of 200 patients, emphasizing the need to monitor durability, delayed complications, and comparative effectiveness.

A 2026 meta-analysis found 32% lower odds of major cardiovascular events with semaglutide, reinforcing cardiovascular benefit while emphasizing baseline risk, evidence limits, and indication-specific interpretation.

A 2026 systematic review found low-certainty evidence that low-dose naltrexone may improve long COVID symptoms, but uncontrolled studies cannot establish efficacy or optimal dosing.